Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pliant Therapeutics Inc (PLRX)

Pliant Therapeutics Inc (PLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pliant Therapeutics to Participate in Upcoming Investor Events

PLRX : 12.98 (+1.01%)
Pliant Therapeutics Presents Positive INTEGRIS-PSC Trial Data at The Liver Meeting® 2024

Pliant Therapeutics presented clinical data on bexotegrast, showing positive effects in primary sclerosing cholangitis at AASLD 2024.Quiver AI SummaryPliant Therapeutics, Inc. announced the presentation...

PLRX : 12.98 (+1.01%)
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

PLRX : 12.98 (+1.01%)
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

PLRX : 12.98 (+1.01%)
Pliant Therapeutics to Participate in the Stifel Healthcare Conference

PLRX : 12.98 (+1.01%)
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

PLRX : 12.98 (+1.01%)
Why Shares of Pliant Therapeutics Are Rising Tuesday

The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.

PLRX : 12.98 (+1.01%)
Why Pliant Therapeutics Stock Is Skyrocketing This Week

The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.

PLRX : 12.98 (+1.01%)
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

PLRX : 12.98 (+1.01%)
NVS : 104.28 (+0.41%)
CPRX : 21.48 (+1.70%)
NBIX : 125.65 (+0.52%)
Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development

PLRX : 12.98 (+1.01%)

Barchart Exclusives

How to Invest for Kids: Understanding the Basics
A good way to show kids the value of compounding money is to ask if they’d rather have a $100 bill today or a penny that doubles every day for 30 days. They will be surprised to hear that in 30 days, that penny would be worth about $5.4 million dollars! Here's a guide to the types of accounts you can open for your children or grandchildren. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar